CLINICAL TRIALS PROFILE FOR TRILIPIX
✉ Email this page to a colleague
All Clinical Trials for Trilipix
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00300430 ↗ | Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. | Completed | Abbott | Phase 3 | 2006-09-01 | The primary purpose of this study is to test the safety and the effects of using an investigational drug regimen; once daily ABT-335 (Investigational drug) administered in combination with once daily atorvastatin calcium, rosuvastatin calcium or simvastatin in patients with abnormal lipid levels in the blood. |
| NCT00639158 ↗ | Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood | Completed | Abbott | Phase 3 | 2008-02-01 | The primary purpose of this study is to compare the safety and efficacy of ABT-335 (investigational drug) coadministered with atorvastatin and ezetimibe to atorvastatin coadministered with ezetimibe in subjects with abnormal lipid (fat) levels in the blood. |
| NCT00813527 ↗ | Effect of Lapaquistat Acetate Combined With Fenofibrate on Blood Cholesterol Levels | Completed | Takeda | Phase 2 | 2006-02-01 | The purpose of this study is to compare changes in cholesterol levels in patients with elevated blood cholesterol with administration of lapaquistat acetate, once daily (QD), and fenofibrate. |
| NCT00839293 ↗ | Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules | Completed | Abbott | Phase 1 | 2009-02-01 | The purpose of this study is to evaluate the safety and compare the bioavailability of fenofibric acid from 2 different dosage strengths of ABT-335. |
| NCT01025492 ↗ | Study of Trilipix Effects on Lipids and Arteries | Terminated | Abbott | Phase 4 | 2009-11-01 | Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance. |
| NCT01025492 ↗ | Study of Trilipix Effects on Lipids and Arteries | Terminated | University of Utah | Phase 4 | 2009-11-01 | Fibrates reduce atherosclerosis and cardiovascular disease events. A major mechanism of this benefit appears to be their ability to raise plasma high density lipoprotein cholesterol (HDL-C), especially in patients with high triglyceride levels. This study will investigate the effects of the addition of Trilipix (fenofibric acid) versus placebo to ongoing statin treatment on high density lipoprotein (HDL) composition and arterial function in subjects with insulin resistance. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Trilipix
Condition Name
Clinical Trial Locations for Trilipix
Trials by Country
Clinical Trial Progress for Trilipix
Clinical Trial Phase
Clinical Trial Sponsors for Trilipix
Sponsor Name
